Latest
Zacks Investment Research Market update
News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 1–19
- Matches
- 19
- Sources here
- 9
- Companies here
- 1
Search results
Stored financial headlines
Active search
19 matching headlines
Ticker or company: VRXAMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Veraxa Biotech Holding AG SEC Filing (Aug 10, 2026)
Veraxa Biotech Holding AG (NASDAQ: VRXA) announced the effectiveness of its F-1 filing with the SEC, dated August 6, 2026, at 4:00 P.M. The filing indicates a neutral impact and sentiment, as analyzed by StockTitan's AI. This notice of effectiveness relates to the company's …
VRXA
main company
Sharemaestro market context
Stored weekly price path
10 weeks -90.6% · Next-week setup negative 26.5%
VERAXA Biotech Advances Antibody Therapeutics with Innovative BiTAC Platform
VERAXA Biotech is making significant strides in antibody therapeutics with its proprietary BiTAC platform, focusing on bispecific ADCs and T-cell engagers. The company's platform is designed for precision and efficacy, positioning it for potential partnerships and licensing deals in the rapidly growing market for …
VRXA
main company
Sharemaestro market context
Stored weekly price path
10 weeks -90.6% · Next-week setup negative 26.5%
VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-G
VERAXA Biotech (NASDAQ: VRXA) has advanced its VXA-222 bispecific antibody-drug conjugate (bsADC) program into the next development stage after successfully completing the discovery phase with OmniAb Inc. The company will now focus on engineering the final therapeutic candidate and conducting preclinical validation. VERAXA also …
VRXA
main company
Sharemaestro market context
Stored weekly price path
10 weeks -90.6% · Next-week setup negative 26.5%
Veraxa Biotech (VRXA) grows patent estate for BiTAC cancer platforms
VERAXA Biotech AG announced it has strengthened its intellectual property for its BiTAC cancer therapy platforms, including T cell engagers (BiTAC-TCE) and antibody-drug-conjugates (BiTAC-ADC). The company filed initial patent applications in the first half of 2026 and now holds over 50 granted patents across …
VRXA
main company
Sharemaestro market context
Stored weekly price path
10 weeks -90.6% · Next-week setup negative 26.5%
Enterprise value to revenue forward of Veraxa Biotech AG – NASDAQ:VRXA
This article provides a brief financial overview of Veraxa Biotech AG (NASDAQ: VRXA), focusing on its enterprise value to revenue forward metric. The content highlights the stock's status on the Nasdaq Stock Market and mentions that the market is currently closed with no trades. …
VRXA
main company
Sharemaestro market context
Stored weekly price path
10 weeks -90.6% · Next-week setup negative 26.5%
VERAXA Biotech (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platform
VERAXA Biotech (VRXA) has expanded its intellectual property portfolio by filing new patent applications for its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company's portfolio now includes over 50 granted patents across 14 countries, with protection expected through at least …
VRXA
main company
Sharemaestro market context
Stored weekly price path
10 weeks -90.6% · Next-week setup negative 26.5%
VERAXA Biotech AG (VRXA) Appoints Christoph Erkel as Chief Scientific Officer
VERAXA Biotech AG (NASDAQ: VRXA) has appointed Christoph Erkel, Ph.D., as its new Chief Scientific Officer. Dr. Erkel, previously VP of R&D, will lead the advancement of the company's BiTAC® platform for developing cancer therapies targeting solid tumors. He brings two decades of experience …
VRXA
main company
Sharemaestro market context
Stored weekly price path
10 weeks -90.6% · Next-week setup negative 26.5%
VERAXA Biotech AG Receives Scientific Advice from Germany’s PEI on BiTAC-TCE Development Program
VERAXA Biotech AG has received Scientific Advice from Germany's Paul-Ehrlich-Institute (PEI) regarding its BiTAC-TCE cancer therapy development program. This consultation provides crucial early validation and clarity on the regulatory path for their novel dual-targeting technology, which has shown promising in vitro and in vivo …
VRXA
main company
Sharemaestro market context
Stored weekly price path
10 weeks -90.6% · Next-week setup negative 26.5%